Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.

Interleukin 2 (IL2) was injected peritumorally and intranodally in 36 patients with unresectable squamous cell carcinoma of the head and neck enrolled in an Eastern Cooperative Oncology Group-sponsored phase Ib trial (EST P-Z388). Groups of 6 patients received escalating doses(200, 2 x 10(3), 2 x 10(4), 2 x 10(5), 2 x 10(6), and 4 x 10(6) units) of IL2 daily 5 times/week for 2 weeks. Tumor biopsies were obtained before and after IL2 therapy. Tumor tissue was provided for histology, and the remaining fresh tissue was divided for snap-freezing in -75 degrees C and for separation of tumor-infiltrating lymphocytes (TIL) and tumor cells. Immunophenotyping of TIL performed on cryostat sections of paired pre- and post-IL2 biopsy tissues showed increases after IL2 therapy in the number of T-cells (P = 0.005), natural killer (NK; CD16+) cells (P = 0.0001), CD25+ cells (P = 0.004), and HLA-DR+ cells (P = 0.001) accumulating in the tumor stroma. In the tumor parenchyma, NK cells (P = 0.0001) and HLA-DR+ cells (P = 0.003) were increased after IL2 therapy. The T:NK cell ratios in the tumor stroma and parenchyma were decreased after therapy, suggesting selective accumulation of NK cells. By flow cytometry, TIL recovered from post-IL2 biopsy tissues were enriched (P < 0.05) in CD3-CD56+ (NK) cells. In situ hybridization with [35S] cDNA probes for cytokines and IL2 receptors indicated that the numbers of cells expressing mRNA for IL2, tumor necrosis factor alpha, IL1-beta, gamma-interferon, transforming growth factor beta, and IL2 receptor p55 or p70 were increased in post-IL2 biopsy tissues as compared to pre-IL2 tissues. Cytolytic activity of TIL isolated from post-IL2 tissues was also increased, as determined in 4-h 51Cr release assays against K562 targets (12 +/- 3 mean lytic units/10(7) cells +/- SEM pre-IL2 versus 46 +/- 13 post-IL2; n = 16) and against autologous tumor (13 +/- 8 versus 68 +/- 26; n = 9). Fresh TIL of one clinical responder showed relatively high levels (195 lytic units) of autotumor cytotoxicity after IL2 therapy versus no activity prior to therapy. In the blood, NK and lymphokine-activated killer cell activity, and percentages of CD3-CD56+ NK cells and of activated (CD25+) T-lymphocytes were increased for all doses of IL2.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  C. Snyderman,et al.  Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[2]  T. Whiteside,et al.  Cytokine production and serum levels in systemic sclerosis. , 1992, Clinical immunology and immunopathology.

[3]  J. Johnson,et al.  Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. , 1992, Cancer research.

[4]  M. Colombo,et al.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.

[5]  T. Whiteside,et al.  Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. , 1992, Journal of immunology.

[6]  T. Whiteside,et al.  Expression of mRNA for cytokines in tumor‐infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer , 1992, International journal of cancer.

[7]  E. Hersh,et al.  Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. , 1991, Journal of the National Cancer Institute.

[8]  C. Snyderman,et al.  Functional and phenotypic analysis of lymphocytes in head and neck cancer. , 1991, Archives of otolaryngology--head & neck surgery.

[9]  G. Forni,et al.  Interleukin‐2 injected around tumor‐draining lymph nodes in head and neck cancer , 1991, Head & neck.

[10]  P. van den Broek,et al.  Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[11]  G. Parmiani,et al.  Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2 , 1990, Tumori.

[12]  G. Forni,et al.  Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[13]  J. Doroshow,et al.  Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[15]  G. Parmiani,et al.  In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. , 1990, Cancer research.

[16]  R. Day,et al.  Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. , 1990, Cancer research.

[17]  C. Snyderman,et al.  Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. , 1990, Cancer research.

[18]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[19]  E. Borden,et al.  Lymphokines and cytokines as cancer treatment.Immunotherapy realized , 1990, Cancer.

[20]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[21]  P. Musiani,et al.  Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. , 1989, Journal of biological response modifiers.

[22]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[23]  H. Huland,et al.  Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. , 1989, Cancer research.

[24]  W. West.  Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. , 1989, Cancer treatment reviews.

[25]  A. Norton.  Pathology of the Head and Neck , 1989 .

[26]  S. Jones,et al.  Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Forni,et al.  Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. , 1988, Progress in experimental tumor research.

[28]  J. Johnson,et al.  Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. , 1987, Cancer research.

[29]  G. Forni,et al.  Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. , 1987, Journal of immunology.

[30]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[31]  T. Whiteside,et al.  Double immunoenzyme staining method for analysis of tissue and blood lymphocyte subsets with monoclonal antibodies. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[32]  S. Rosenberg,et al.  Intraperitoneal administration of interleukin-2 in patients with cancer. , 1986, Archives of surgery.

[33]  B. Brown,et al.  Natural killer cell activity and head and neck cancer: a clinical assessment. , 1986, Journal of the National Cancer Institute.

[34]  I. Tannock,et al.  Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Baseler,et al.  Immune complexes, serum proteins, cell‐mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck , 1986, Cancer.

[36]  G. Forni,et al.  Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. , 1985, Journal of immunology.

[37]  A. Feinberg,et al.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. , 1984, Analytical biochemistry.

[38]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[39]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[40]  G. A. Mack,et al.  K-Sample Rank Tests for Umbrella Alternatives , 1981 .